Navigation Links
DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement

PARSIPPANY, N.J. and LEIPZIG, Germany, Dec. 15 2010 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology.

The agreement grants DSM rights to c-LEcta's proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates. Germany-based c-LEcta is an industrial biotechnology company developing and implementing sustainable and economic industrial processes based on customized enzymes and microbial production strains.

Based on its patent-protected technology platform for the identification and optimization of biocatalysts, cLEcta has built up a unique collection of several hundred enzymes and qualified enzyme mutants. Alcohol dehydrogenases make up one of the important enzyme classes in this field and can be used for the cost efficient synthesis of chiral alcohols from ketones with extraordinary purities.

DSM applies their InnoSyn™ route scouting to identify more cost efficient routes for the development and manufacture of drug intermediates and ingredients by combining biocatalytic solutions with advanced chemical and process technologies. The new routes result in shorter cycle times due to fewer steps in the process with the same reliability and quality using more renewable starting materials. DSM, a global leader in industrial biocatalysis, continuously broadens its enzyme platforms by in-house developments and partnering models with innovative biotech companies such as c-LEcta.

Dr. Oliver May, Business Manager for DSM comments: "This agreement further broadens our alcohol dehydrogenase platform which we set up for rapid screening programs for our customers and the development of cost efficient production of a large spectrum of chiral secondary alcohols."

DSM will also provide commercialization of sustainable enzyme-based manufacturing routes developed by their InnoSyn™ route scouting services for c-LEcta.

Dr. Thomas Greiner-Stoffele, Chief Scientific Officer for c-LEcta added: "We are pleased to have this cooperation with DSM which will give us very useful benchmarks for our alcohol dehydrogenase collection. We are constantly expanding our biocatalysts collection with unique enzymes from biodiversity and engineering projects to provide solutions also for challenging targets."

InnoSyn™ is a trademark of DSM

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information:

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

c-LEcta GmbH c-LEcta is a German biotechnology company focusing on the provision of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering is used for the efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes in biodiversity and for effective enzyme engineering.

More information:

For more information:DSM Innovative Synthesis BV

c-LEcta GmbHOliver May, Ph.D.

Andreas Buthe, Ph.D.Business Manager, InnoSyn™

Business Development Managertel. +31 (46) 4760551

tel. +49 341 355  

fax +49 341 355 Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TransTech Medical Solutions Expands Offering to MD Anderson Cancer Center to Include Outsourced Medical Transcription and Editing Services
2. Texas-Based Healthcare Delivery System Expands Utilization of Streamline Health Document Workflow Solutions
3. Menicon Expands Partnership with Optimed in North America
4. Protein Sciences Expands License Agreement with UMN Pharma
5. Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions
6. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
7. CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times
8. Next Intelligence Health Expands US Channel Program
9. Caliper Life Sciences Expands Offering for Next Generation Sequencing Workflows
10. Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey
11. Verizon Expands Medical Data Exchange to Include Broader Range of Patient Health Data
Post Your Comments:
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
Breaking Medicine News(10 mins):